vs

Side-by-side financial comparison of SR Bancorp, Inc. (SRBK) and UTAH MEDICAL PRODUCTS INC (UTMD). Click either name above to swap in a different company.

UTAH MEDICAL PRODUCTS INC is the larger business by last-quarter revenue ($9.0M vs $8.4M, roughly 1.1× SR Bancorp, Inc.). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs 10.0%, a 18.4% gap on every dollar of revenue. On growth, SR Bancorp, Inc. posted the faster year-over-year revenue change (6.4% vs -1.2%). UTAH MEDICAL PRODUCTS INC produced more free cash flow last quarter ($3.4M vs $3.1M). Over the past eight quarters, SR Bancorp, Inc.'s revenue compounded faster (-2.4% CAGR vs -10.7%).

SR Bancorp Inc. is a regional bank holding company based in the United States. It offers a full range of consumer and commercial banking services including deposit products, personal loans, mortgage lending, small business financing, and commercial credit solutions, primarily serving local communities and small to mid-sized enterprises in its operating areas.

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

SRBK vs UTMD — Head-to-Head

Bigger by revenue
UTMD
UTMD
1.1× larger
UTMD
$9.0M
$8.4M
SRBK
Growing faster (revenue YoY)
SRBK
SRBK
+7.7% gap
SRBK
6.4%
-1.2%
UTMD
Higher net margin
UTMD
UTMD
18.4% more per $
UTMD
28.4%
10.0%
SRBK
More free cash flow
UTMD
UTMD
$270.0K more FCF
UTMD
$3.4M
$3.1M
SRBK
Faster 2-yr revenue CAGR
SRBK
SRBK
Annualised
SRBK
-2.4%
-10.7%
UTMD

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
SRBK
SRBK
UTMD
UTMD
Revenue
$8.4M
$9.0M
Net Profit
$834.0K
$2.6M
Gross Margin
58.2%
Operating Margin
13.0%
27.0%
Net Margin
10.0%
28.4%
Revenue YoY
6.4%
-1.2%
Net Profit YoY
-18.3%
-11.6%
EPS (diluted)
$0.11
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SRBK
SRBK
UTMD
UTMD
Q4 25
$8.4M
$9.0M
Q3 25
$8.2M
$9.8M
Q2 25
$7.6M
$10.0M
Q1 25
$7.7M
$9.7M
Q4 24
$7.9M
$9.2M
Q3 24
$8.4M
$10.0M
Q2 24
$7.9M
$10.4M
Q1 24
$8.8M
$11.3M
Net Profit
SRBK
SRBK
UTMD
UTMD
Q4 25
$834.0K
$2.6M
Q3 25
$693.0K
$2.6M
Q2 25
$2.2M
$3.0M
Q1 25
$537.0K
$3.0M
Q4 24
$1.0M
$2.9M
Q3 24
$1.4M
$3.6M
Q2 24
$-3.0M
$3.5M
Q1 24
$1.1M
$4.0M
Gross Margin
SRBK
SRBK
UTMD
UTMD
Q4 25
58.2%
Q3 25
57.1%
Q2 25
56.2%
Q1 25
57.0%
Q4 24
58.1%
Q3 24
58.0%
Q2 24
60.1%
Q1 24
59.7%
Operating Margin
SRBK
SRBK
UTMD
UTMD
Q4 25
13.0%
27.0%
Q3 25
11.0%
26.6%
Q2 25
32.1%
32.1%
Q1 25
8.1%
32.5%
Q4 24
17.1%
32.0%
Q3 24
20.6%
33.4%
Q2 24
-34.0%
33.1%
Q1 24
15.4%
34.2%
Net Margin
SRBK
SRBK
UTMD
UTMD
Q4 25
10.0%
28.4%
Q3 25
8.5%
26.8%
Q2 25
29.2%
30.6%
Q1 25
7.0%
31.3%
Q4 24
13.0%
31.7%
Q3 24
16.3%
35.6%
Q2 24
-38.2%
33.2%
Q1 24
12.1%
34.9%
EPS (diluted)
SRBK
SRBK
UTMD
UTMD
Q4 25
$0.11
$0.80
Q3 25
$0.09
$0.82
Q2 25
$0.27
$0.94
Q1 25
$0.06
$0.92
Q4 24
$0.12
$0.86
Q3 24
$0.16
$1.03
Q2 24
$8.14
$0.98
Q1 24
$0.12
$1.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SRBK
SRBK
UTMD
UTMD
Cash + ST InvestmentsLiquidity on hand
$81.8M
$85.8M
Total DebtLower is stronger
$225.0K
Stockholders' EquityBook value
$188.5M
$119.3M
Total Assets
$1.1B
$122.5M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SRBK
SRBK
UTMD
UTMD
Q4 25
$81.8M
$85.8M
Q3 25
$58.3M
$84.3M
Q2 25
$57.8M
$82.2M
Q1 25
$62.2M
$83.3M
Q4 24
$53.4M
$83.0M
Q3 24
$47.3M
$88.5M
Q2 24
$45.9M
$89.2M
Q1 24
$72.5M
$93.8M
Total Debt
SRBK
SRBK
UTMD
UTMD
Q4 25
$225.0K
Q3 25
Q2 25
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
SRBK
SRBK
UTMD
UTMD
Q4 25
$188.5M
$119.3M
Q3 25
$191.9M
$118.3M
Q2 25
$193.8M
$117.5M
Q1 25
$195.1M
$117.0M
Q4 24
$198.1M
$117.4M
Q3 24
$200.5M
$124.2M
Q2 24
$199.5M
$124.1M
Q1 24
$199.3M
$127.7M
Total Assets
SRBK
SRBK
UTMD
UTMD
Q4 25
$1.1B
$122.5M
Q3 25
$1.1B
$122.0M
Q2 25
$1.1B
$120.8M
Q1 25
$1.1B
$122.5M
Q4 24
$1.1B
$122.5M
Q3 24
$1.1B
$129.7M
Q2 24
$1.0B
$130.0M
Q1 24
$1.1B
$135.4M
Debt / Equity
SRBK
SRBK
UTMD
UTMD
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SRBK
SRBK
UTMD
UTMD
Operating Cash FlowLast quarter
$3.6M
$3.5M
Free Cash FlowOCF − Capex
$3.1M
$3.4M
FCF MarginFCF / Revenue
37.0%
37.2%
Capex IntensityCapex / Revenue
5.9%
1.2%
Cash ConversionOCF / Net Profit
4.31×
1.36×
TTM Free Cash FlowTrailing 4 quarters
$11.0M
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SRBK
SRBK
UTMD
UTMD
Q4 25
$3.6M
$3.5M
Q3 25
$1.2M
$3.9M
Q2 25
$4.7M
$2.9M
Q1 25
$2.6M
$4.5M
Q4 24
$-1.4M
$2.9M
Q3 24
$1.8M
$3.9M
Q2 24
$-1.7M
$2.8M
Q1 24
$-3.9M
$5.3M
Free Cash Flow
SRBK
SRBK
UTMD
UTMD
Q4 25
$3.1M
$3.4M
Q3 25
$1.1M
$3.9M
Q2 25
$4.2M
$2.8M
Q1 25
$2.5M
$4.3M
Q4 24
$-1.5M
$2.9M
Q3 24
$1.7M
$3.8M
Q2 24
$-2.8M
$2.7M
Q1 24
$-4.0M
$5.3M
FCF Margin
SRBK
SRBK
UTMD
UTMD
Q4 25
37.0%
37.2%
Q3 25
14.0%
39.2%
Q2 25
55.9%
28.4%
Q1 25
32.3%
44.1%
Q4 24
-19.5%
32.0%
Q3 24
20.3%
37.7%
Q2 24
-35.8%
25.5%
Q1 24
-45.2%
46.3%
Capex Intensity
SRBK
SRBK
UTMD
UTMD
Q4 25
5.9%
1.2%
Q3 25
0.9%
0.3%
Q2 25
5.7%
0.5%
Q1 25
1.0%
1.9%
Q4 24
1.3%
0.1%
Q3 24
1.0%
0.9%
Q2 24
13.9%
1.1%
Q1 24
0.5%
0.2%
Cash Conversion
SRBK
SRBK
UTMD
UTMD
Q4 25
4.31×
1.36×
Q3 25
1.76×
1.47×
Q2 25
2.11×
0.94×
Q1 25
4.79×
1.47×
Q4 24
-1.40×
1.01×
Q3 24
1.31×
1.08×
Q2 24
0.80×
Q1 24
-3.69×
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons